+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.

Age: 50Years - 85YearsAll GendersPhase 2
80 locations
P

Actively Recruiting

Researchers are evaluating how the drug LY3439539 affects certain proteins in the spinal fluid of people with Alzheimers disease. This Phase 1, open-label study focuses on changes in cerebrospinal fluid biomarkers related to Alzheimers, aiming to better understand the disease process. It is sponsored by Eli Lilly and Company and targets participants with symptomatic Alzheimers disease. Participants will receive multiple doses of LY3439539 administered intravenously. The study is designed as a single group without a placebo comparison. The treatment period includes repeated dosing, followed by a follow-up period lasting up to 24 weeks to assess changes in biomarkers. The total participation time is approximately 9 months with visits roughly once a month. During the study, participants will undergo lumbar punctures for cerebrospinal fluid collection as well as blood tests to measure biomarker levels. Researchers will monitor changes in neurofilament light chain and phospho-tau proteins as primary and secondary outcomes. Safety and pharmacokinetics of LY3439539 will also be assessed. Participants will have regular visits for assessments and monitoring throughout the study duration.

Age: 50Years - 85YearsAll GendersPhase 1
16 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in treating cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to improve thinking abilities measured by specific standardized assessments. Participants will receive either KarXT plus KarX-EC or a placebo at specified doses on designated days. The study lasts 24 weeks, during which outcomes like changes in cognitive function, daily living activities, and behavioral symptoms will be assessed. The trial includes an active comparison group and a placebo group to evaluate treatment effects. Throughout the study, participants and their caregivers will attend regular visits for clinical assessments, including cognitive tests ADAS-Cog11, caregiver interviews, and monitoring of adverse events and vital signs. Researchers will carefully track safety and treatment response over the 24-week period to understand the impact of the study drugs on Alzheimers symptoms.

Age: 60Years - 85YearsAll GendersPhase 3
128 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of SAR448851, an oral medication taken once daily, in people with early Alzheimers disease, including mild cognitive impairment due to Alzheimers and mild Alzheimers dementia. This Phase 2 randomized, placebo-controlled study focuses on participants aged 55 to 85 years who have evidence of cerebral amyloid pathology. The study aims to measure changes in plasma biomarkers and monitor safety outcomes over time. Participants are randomly assigned to receive either SAR448851 at one of two doses or a placebo, taken orally once daily for 48 weeks during Part A. Those who complete Part A can join an open-label extension in Part B. The total study duration may last up to 111 weeks for Parts A and B, or up to 63 weeks for the optional dose 2 cohort. Various assessments, including brain imaging and fluid biomarker measurements, will be used to evaluate treatment effects. Throughout the trial, participants will have regular evaluations including brain MRIs to monitor for adverse events such as ARIA-E and ARIA-H, laboratory tests, vital sign checks, ECGs, and cognitive assessments. Researchers will track changes in Alzheimers disease biomarkers from baseline through Week 96. Safety and tolerability will be continuously assessed, and participants cognitive status will be monitored to understand the treatments impact over time.

Age: 55Years - 85YearsAll GendersPhase 2
20 locations
S

Actively Recruiting

Researchers are evaluating the safety of abdominal vagus nerve stimulation aVNS for adults with moderate to severe rheumatoid arthritis RA that has not improved with medication. This open-label study focuses on adult-onset RA patients who have drug-refractory symptoms. The goal is to assess safety, device performance, and any potential benefits of the aVNS device over time. Participants will have the aVNS device implanted through keyhole surgery. Starting two weeks after implantation, stimulation will be delivered daily for about 3 hours per day over a 22-week period. The device is controlled by the participant using a controller to switch it on and off. After this initial phase, participants may continue using the device, which will stay implanted unless removal is clinically needed or requested by the participant. Throughout the study, participants will undergo clinical assessments of RA symptoms and device performance at 2, 6, 12, and 24 weeks post-surgery. Following the initial treatment phase, participants will be monitored twice yearly for up to 5 years to track safety and device effects. Total participation in the trial lasts about 5 years, including follow-up monitoring and evaluations.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
3 locations
P

Actively Recruiting

Researchers are studying participants with chronic Venous Leg Ulcers VLUs to see if adding TR987 0.1% gel to the Standard of Care improves healing compared to Standard of Care alone. This Phase 3, randomized, double-blind trial aims to evaluate the effectiveness and safety of the TR987 gel in treating VLUs, a type of non-healing wound caused by venous insufficiency. Participants will be assigned to one of two groups one group will receive TR987 0.1% gel applied topically along with Standard of Care treatments like wound cleansing, dressings, and compression bandaging the other group will receive Standard of Care alone. Treatments will be applied twice weekly for the first four weeks, then once weekly for the following 12 weeks, totaling up to 16 weeks of treatment. During the study, participants will have their target ulcer monitored for complete closure at various time points, including the 12- and 16-week marks, as well as follow-up at three months after closure. Pain levels and changes in ulcer size will also be assessed. Safety and tolerability will be tracked throughout the trial. Participation involves regular visits for treatment and evaluation over the 16-week treatment period, with additional follow-up to assess lasting ulcer closure.

Age: 18Years +All GendersPhase 3
12 locations